Trial Profile

A Phase 4, Multicenter, Open-Label Study to Evaluate the Safety and Pharmacokinetics of N1539 in Children 2 to <17 Years of Age Following Surgery

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 19 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Meloxicam (Primary)
Indications Postoperative pain
Focus Adverse reactions
Sponsors Baudax Bio

Most Recent Events

28 Jul 2023 Pharmacokinetics endpoint removed from primary outcome measures.
28 Jul 2023 Status changed from recruiting to discontinued (Anjeso (N1539) NDA Withdrawn).
04 May 2022 According to a Baudax Bio media release, first cohort has been dosed and the study has enrolled one of the cohort groups of surgical patients during the first quarter of 2022.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com